LGALS1 and neoplasm: In anti-VEGF refractory tumors, galectin-1 secretion increased together with its enhanced binding to neovascular endothelial cells due to altered glycosylation patterns on VEGFR2 (i.e., decreased α2,6-linked sialic acid), leading to galectin-1-driven angiogenesis and tumor progression14.